JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310

Benzinga · 3d ago
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $300 to $310.